Antimicrobial activity of SM-17466, a novel carbapenem antibiotic with potent activity against methicillin-resistant Staphylococcus aureus

Yoshihiro Sumita, H. Nouda, K. Kanazawa, M. Fukasawa

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The in vitro and in vivo antibacterial activities of SM-17466, a new 1β- methyl carbapenem, were evaluated against a wide range of clinical bacterial isolates and compared with the activities of meropenem, imipenem, vancomycin, and arbekacin. SM-17466 had a broad spectrum of action against gram-positive bacteria, showing especially potent activity against methicillin-resistant staphylococci. The MICs of SM-17466, meropenem, imipenem, vancomycin, and arbekacin at which 90% of clinical isolates of methicillin-resistant Staphylococcus aureus were inhibited were 3.13, 50, 100, 1.56, and 3.13 μg/ml, respectively. This activity of SM-17466 was almost equivalent to those of the antibiotics used for the treatment of infections caused by this organism. SM-17466 also showed bactericidal activity against methicillin- resistant S. aureus. In contrast, SM-17466 was less active against gram- negative bacteria, especially against Pseudomonas aeruginosa, compared with the other carbapenems; however, of the carbapenems, SM-17466 exhibited the highest activity against Haemophilus influenzae and Bacteroides fragilis. SM- 17466, at a 50% inhibitory concentration of less than 1 μg/ml, bound to penicillin-binding proteins 1 to 4 in methicillin-susceptible S. aureus and also had good binding to penicillin-binding protein 2' in a methicillin- resistant strain (50% inhibitory concentration, 5.9 μg/ml). This high affinity, which was 10 and 20 times greater than those for meropenem and imipenem, respectively, was reflected in the potent activity of SM-17466 against methicillin-resistant S. aureus. SM-17466 demonstrated excellent in vivo efficacy against methicillin-susceptible and -resistant S. aureus strains in a mouse peritoneal infection model: the efficacy of SM-17466 against methicillin-resistant strains was equal to or one-third that of vancomycin. This activity was comparable to the in vitro activity of SM- 17466. The subcutaneous injection of SM-17466 in mice revealed that the half- life of SM-17466 in serum was about 18 min, intermediate between those of vancomycin and arbekacin and 1.5-fold that of imipenem-cilastatin. SM-17466 was resistant to hydrolysis by swine renal dehydropeptidase 1, to an extent comparable to the resistance shown by meropenem.

Original languageEnglish
Pages (from-to)910-916
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume39
Issue number4
DOIs
Publication statusPublished - Jan 1 1995
Externally publishedYes

Fingerprint

Carbapenems
Methicillin-Resistant Staphylococcus aureus
meropenem
Vancomycin
Methicillin Resistance
Imipenem
Penicillin-Binding Proteins
SM 17466
Inhibitory Concentration 50
Bacteroides fragilis
Methicillin
Haemophilus influenzae
Gram-Positive Bacteria
Subcutaneous Injections
Infection
Gram-Negative Bacteria
Staphylococcus
Pseudomonas aeruginosa

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Antimicrobial activity of SM-17466, a novel carbapenem antibiotic with potent activity against methicillin-resistant Staphylococcus aureus. / Sumita, Yoshihiro; Nouda, H.; Kanazawa, K.; Fukasawa, M.

In: Antimicrobial Agents and Chemotherapy, Vol. 39, No. 4, 01.01.1995, p. 910-916.

Research output: Contribution to journalArticle

@article{43cb04c355124cbf9542f0bdfc4902b5,
title = "Antimicrobial activity of SM-17466, a novel carbapenem antibiotic with potent activity against methicillin-resistant Staphylococcus aureus",
abstract = "The in vitro and in vivo antibacterial activities of SM-17466, a new 1β- methyl carbapenem, were evaluated against a wide range of clinical bacterial isolates and compared with the activities of meropenem, imipenem, vancomycin, and arbekacin. SM-17466 had a broad spectrum of action against gram-positive bacteria, showing especially potent activity against methicillin-resistant staphylococci. The MICs of SM-17466, meropenem, imipenem, vancomycin, and arbekacin at which 90{\%} of clinical isolates of methicillin-resistant Staphylococcus aureus were inhibited were 3.13, 50, 100, 1.56, and 3.13 μg/ml, respectively. This activity of SM-17466 was almost equivalent to those of the antibiotics used for the treatment of infections caused by this organism. SM-17466 also showed bactericidal activity against methicillin- resistant S. aureus. In contrast, SM-17466 was less active against gram- negative bacteria, especially against Pseudomonas aeruginosa, compared with the other carbapenems; however, of the carbapenems, SM-17466 exhibited the highest activity against Haemophilus influenzae and Bacteroides fragilis. SM- 17466, at a 50{\%} inhibitory concentration of less than 1 μg/ml, bound to penicillin-binding proteins 1 to 4 in methicillin-susceptible S. aureus and also had good binding to penicillin-binding protein 2' in a methicillin- resistant strain (50{\%} inhibitory concentration, 5.9 μg/ml). This high affinity, which was 10 and 20 times greater than those for meropenem and imipenem, respectively, was reflected in the potent activity of SM-17466 against methicillin-resistant S. aureus. SM-17466 demonstrated excellent in vivo efficacy against methicillin-susceptible and -resistant S. aureus strains in a mouse peritoneal infection model: the efficacy of SM-17466 against methicillin-resistant strains was equal to or one-third that of vancomycin. This activity was comparable to the in vitro activity of SM- 17466. The subcutaneous injection of SM-17466 in mice revealed that the half- life of SM-17466 in serum was about 18 min, intermediate between those of vancomycin and arbekacin and 1.5-fold that of imipenem-cilastatin. SM-17466 was resistant to hydrolysis by swine renal dehydropeptidase 1, to an extent comparable to the resistance shown by meropenem.",
author = "Yoshihiro Sumita and H. Nouda and K. Kanazawa and M. Fukasawa",
year = "1995",
month = "1",
day = "1",
doi = "10.1128/AAC.39.4.910",
language = "English",
volume = "39",
pages = "910--916",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Antimicrobial activity of SM-17466, a novel carbapenem antibiotic with potent activity against methicillin-resistant Staphylococcus aureus

AU - Sumita, Yoshihiro

AU - Nouda, H.

AU - Kanazawa, K.

AU - Fukasawa, M.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - The in vitro and in vivo antibacterial activities of SM-17466, a new 1β- methyl carbapenem, were evaluated against a wide range of clinical bacterial isolates and compared with the activities of meropenem, imipenem, vancomycin, and arbekacin. SM-17466 had a broad spectrum of action against gram-positive bacteria, showing especially potent activity against methicillin-resistant staphylococci. The MICs of SM-17466, meropenem, imipenem, vancomycin, and arbekacin at which 90% of clinical isolates of methicillin-resistant Staphylococcus aureus were inhibited were 3.13, 50, 100, 1.56, and 3.13 μg/ml, respectively. This activity of SM-17466 was almost equivalent to those of the antibiotics used for the treatment of infections caused by this organism. SM-17466 also showed bactericidal activity against methicillin- resistant S. aureus. In contrast, SM-17466 was less active against gram- negative bacteria, especially against Pseudomonas aeruginosa, compared with the other carbapenems; however, of the carbapenems, SM-17466 exhibited the highest activity against Haemophilus influenzae and Bacteroides fragilis. SM- 17466, at a 50% inhibitory concentration of less than 1 μg/ml, bound to penicillin-binding proteins 1 to 4 in methicillin-susceptible S. aureus and also had good binding to penicillin-binding protein 2' in a methicillin- resistant strain (50% inhibitory concentration, 5.9 μg/ml). This high affinity, which was 10 and 20 times greater than those for meropenem and imipenem, respectively, was reflected in the potent activity of SM-17466 against methicillin-resistant S. aureus. SM-17466 demonstrated excellent in vivo efficacy against methicillin-susceptible and -resistant S. aureus strains in a mouse peritoneal infection model: the efficacy of SM-17466 against methicillin-resistant strains was equal to or one-third that of vancomycin. This activity was comparable to the in vitro activity of SM- 17466. The subcutaneous injection of SM-17466 in mice revealed that the half- life of SM-17466 in serum was about 18 min, intermediate between those of vancomycin and arbekacin and 1.5-fold that of imipenem-cilastatin. SM-17466 was resistant to hydrolysis by swine renal dehydropeptidase 1, to an extent comparable to the resistance shown by meropenem.

AB - The in vitro and in vivo antibacterial activities of SM-17466, a new 1β- methyl carbapenem, were evaluated against a wide range of clinical bacterial isolates and compared with the activities of meropenem, imipenem, vancomycin, and arbekacin. SM-17466 had a broad spectrum of action against gram-positive bacteria, showing especially potent activity against methicillin-resistant staphylococci. The MICs of SM-17466, meropenem, imipenem, vancomycin, and arbekacin at which 90% of clinical isolates of methicillin-resistant Staphylococcus aureus were inhibited were 3.13, 50, 100, 1.56, and 3.13 μg/ml, respectively. This activity of SM-17466 was almost equivalent to those of the antibiotics used for the treatment of infections caused by this organism. SM-17466 also showed bactericidal activity against methicillin- resistant S. aureus. In contrast, SM-17466 was less active against gram- negative bacteria, especially against Pseudomonas aeruginosa, compared with the other carbapenems; however, of the carbapenems, SM-17466 exhibited the highest activity against Haemophilus influenzae and Bacteroides fragilis. SM- 17466, at a 50% inhibitory concentration of less than 1 μg/ml, bound to penicillin-binding proteins 1 to 4 in methicillin-susceptible S. aureus and also had good binding to penicillin-binding protein 2' in a methicillin- resistant strain (50% inhibitory concentration, 5.9 μg/ml). This high affinity, which was 10 and 20 times greater than those for meropenem and imipenem, respectively, was reflected in the potent activity of SM-17466 against methicillin-resistant S. aureus. SM-17466 demonstrated excellent in vivo efficacy against methicillin-susceptible and -resistant S. aureus strains in a mouse peritoneal infection model: the efficacy of SM-17466 against methicillin-resistant strains was equal to or one-third that of vancomycin. This activity was comparable to the in vitro activity of SM- 17466. The subcutaneous injection of SM-17466 in mice revealed that the half- life of SM-17466 in serum was about 18 min, intermediate between those of vancomycin and arbekacin and 1.5-fold that of imipenem-cilastatin. SM-17466 was resistant to hydrolysis by swine renal dehydropeptidase 1, to an extent comparable to the resistance shown by meropenem.

UR - http://www.scopus.com/inward/record.url?scp=0028970114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028970114&partnerID=8YFLogxK

U2 - 10.1128/AAC.39.4.910

DO - 10.1128/AAC.39.4.910

M3 - Article

C2 - 7785994

AN - SCOPUS:0028970114

VL - 39

SP - 910

EP - 916

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -